These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24691740)

  • 1. MG132 reverse the malignant characteristics of hypopharyngeal cancer.
    Ma J; Yu L; Tian J; Mu Y; Lv Z; Zou J; Li J; Wang H; Xu W
    Mol Med Rep; 2014 Jun; 9(6):2587-91. PubMed ID: 24691740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FaDu cell characteristics induced by multidrug resistance.
    Ma J; Lu S; Yu L; Tian J; Li J; Wang H; Xu W
    Oncol Rep; 2011 Nov; 26(5):1189-95. PubMed ID: 21833476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MG‑132 reverses multidrug resistance by activating the JNK signaling pathway in FaDu/T cells.
    Ma J; Lv Z; Liu X; Liu X; Xu W
    Mol Med Rep; 2018 Aug; 18(2):1820-1825. PubMed ID: 29901180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of ABCB1 and ABCG2 in the multidrug resistance of hypopharyngeal carcinoma FaDu cell line].
    MA JK; LU SM; YU L; TIAN JJ; LI JF; WANG HB; XU W
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Apr; 47(4):305-10. PubMed ID: 22800348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo.
    Ren X; Liu H; Zhang M; Wang M; Ma S
    Mol Med Rep; 2016 Sep; 14(3):2431-8. PubMed ID: 27484725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reversion of resistance to cisplatin induced by MG132 in cervical cancer line HCE1 multicellular spheroid].
    Wu YL; Yang HJ; Wang KK; Tao GS; Liu YZ; Hu Y
    Zhonghua Fu Chan Ke Za Zhi; 2010 Apr; 45(4):287-91. PubMed ID: 20646542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a.
    Qiang W; Sui F; Ma J; Li X; Ren X; Shao Y; Liu J; Guan H; Shi B; Hou P
    Endocrine; 2017 Apr; 56(1):98-108. PubMed ID: 28220348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells.
    Giuliano M; Lauricella M; Calvaruso G; Carabillò M; Emanuele S; Vento R; Tesoriere G
    Cancer Res; 1999 Nov; 59(21):5586-95. PubMed ID: 10554039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation of expression of P-glycoprotein and inhibitor of apoptosis proteins to chemosensitivity in gastrointestinal carcinoma tissues].
    Han J; Tan BB; Geng W; Lu BR; Zhao JH
    Ai Zheng; 2008 Nov; 27(11):1166-71. PubMed ID: 19000447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
    Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
    Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance.
    Fujita T; Washio K; Takabatake D; Takahashi H; Yoshitomi S; Tsukuda K; Ishibe Y; Ogasawara Y; Doihara H; Shimizu N
    Int J Cancer; 2005 Nov; 117(4):670-82. PubMed ID: 15945097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome Inhibitor Carbobenzoxy-L-Leucyl-L-Leucyl-L-Leucinal (MG132) Enhances Therapeutic Effect of Paclitaxel on Breast Cancer by Inhibiting Nuclear Factor (NF)-κB Signaling.
    Zhang Y; Yang B; Zhao J; Li X; Zhang L; Zhai Z
    Med Sci Monit; 2018 Jan; 24():294-304. PubMed ID: 29332931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-κB transcription factor.
    Yu LL; Wu JG; Dai N; Yu HG; Si JM
    Oncol Rep; 2011 Nov; 26(5):1197-203. PubMed ID: 21811763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The different regulatory effects of p53 status on multidrug resistance are determined by autophagy in ovarian cancer cells.
    Kong D; Ma S; Liang B; Yi H; Zhao Y; Xin R; Cui L; Jia L; Liu X; Liu X
    Biomed Pharmacother; 2012 Jun; 66(4):271-8. PubMed ID: 22564245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells.
    Li X; Huang T; Jiang G; Gong W; Qian H; Zou C
    Biochem Biophys Res Commun; 2013 Sep; 439(2):179-86. PubMed ID: 23994633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation.
    Gibalová L; Sereš M; Rusnák A; Ditte P; Labudová M; Uhrík B; Pastorek J; Sedlák J; Breier A; Sulová Z
    Toxicol In Vitro; 2012 Apr; 26(3):435-44. PubMed ID: 22269388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
    Biskup E; Kamstrup MR; Manfé V; Gniadecki R
    Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp.
    Zhang Y; Shi Y; Li X; Du R; Luo G; Xia L; Du W; Chen B; Zhai H; Wu K; Fan D
    Cancer Biol Ther; 2008 Apr; 7(4):540-6. PubMed ID: 18296917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.
    Hougardy BM; Maduro JH; van der Zee AG; de Groot DJ; van den Heuvel FA; de Vries EG; de Jong S
    Int J Cancer; 2006 Apr; 118(8):1892-900. PubMed ID: 16287099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.